Recently, Shanghai Sunshine pharmaceutical procurement network issued the notice on publishing the first year's agreed procurement volume of national centralized drug procurement (insulin special), which stipulates that the results of this special centralized procurement of insulin will be implemented in May 2022, and the specific implementation date shall be subject to the notice issued by all localities. According to the work arrangement, all pharmaceutical institutions have completed the confirmation of the agreed procurement volume of the selected products in the insulin special project in accordance with the provisions of the national centralized drug procurement document (insulin special project) (gy-yd2021-3). The national organization of centralized drug procurement (insulin special project) has determined the national agreed procurement volume in the first year and the regional agreed procurement volume in the first year. The notice points out that the medical insurance departments of each province can log in to the "comprehensive service platform for centralized drug procurement organized by the state" and click the "view the agreed purchase quantity" menu in the "agreed purchase quantity management" on the left to view the agreed purchase quantity of the selected enterprises in the Province. Each insulin winning enterprise can log in to the "comprehensive service platform for centralized drug procurement organized by the state", and click the "view agreed purchase quantity" menu in the "national procurement bidding management" on the left to view the agreed purchase quantity of the selected products of the enterprise. It is reported that insulin is an important drug for diabetics to control blood sugar and plays an irreplaceable role in the treatment of diabetes. Because insulin needs to be used for a long time, the falsely high price brings a heavy burden to patients. This special purchase of insulin is the first time that the state organizes the centralized purchase of drugs to expand to the field of biological drugs. It is an important milestone in the process of centralized purchase reform. It not only promotes the return of insulin price to a reasonable level and benefits more patients, but also is of great significance to improve the centralized purchase system and achieve the reform goal. (outlook new era)